 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...121122123124125126127128129130131132133» |
- ||||| Votrient (pazopanib) / Novartis, BeiGene
New P2 trial, Metastases: CATChEz: Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Mar 5, 2012
P2, N=74, Active, not recruiting, Sponsor: GlaxoSmithKline
- |||||||||| everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
New P3 trial: Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients (clinicaltrials.gov) - Mar 4, 2012
P3, N=106, Recruiting, Sponsor: Novartis Pharmaceuticals
- || cisplatin / Generic mfg., everolimus / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed: Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy (clinicaltrials.gov) - Mar 4, 2012
P1, N=52, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting
- everolimus / Generic mfg., paclitaxel / Generic mfg.
Trial termination: Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma (clinicaltrials.gov) - Feb 29, 2012
P2, N=28, Terminated, Sponsor: Heinrich-Heine University, Duesseldorf
Recruiting --> Active, not recruiting Recruiting --> Terminated; delayed recruitment
- Sutent (sunitinib) / Pfizer
Enrollment closed, Metastases: TSAP: Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study (clinicaltrials.gov) - Feb 29, 2012
P=N/A, N=45, Active, not recruiting, Sponsor: VU University Medical Center
Recruiting --> Terminated; delayed recruitment Recruiting --> Active, not recruiting
- figitumumab (CP-751,871) / Novartis
Enrollment change, Combination therapy, Metastases: RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms (clinicaltrials.gov) - Feb 23, 2012
P1, N=21, Completed, Sponsor: Suzanne George, MD
Recruiting --> Active, not recruiting N=33 --> 21
- ||| buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment open, Metastases: A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies (clinicaltrials.gov) - Feb 23, 2012
P1, N=53, Recruiting, Sponsor: Emory University
N=33 --> 21 Not yet recruiting --> Recruiting
- figitumumab (CP-751,871) / Novartis
Trial completion, Combination therapy, Metastases: RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms (clinicaltrials.gov) - Feb 23, 2012
P1, N=21, Completed, Sponsor: Suzanne George, MD
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- robatumumab (SCH 717454) / Merck (MSD)
Trial termination, Combination therapy, Metastases: Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) (clinicaltrials.gov) - Feb 20, 2012
P1b/2, N=15, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Completed --> Terminated; This study was terminated for business reasons.
- ||| Farydak (panobinostat) / Secura Bio
Trial initiation date: Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Feb 16, 2012
P2, N=75, Recruiting, Sponsor: Anne Beaven
Completed --> Terminated; This study was terminated for business reasons. Initiation date: Sep 2009 --> Feb 2012
- everolimus / Generic mfg., sorafenib / Generic mfg.
Enrollment change, Metastases: Sorafenib and RAD001 Renal Cell Carcinoma (clinicaltrials.gov) - Feb 8, 2012
P1, N=21, Active, not recruiting, Sponsor: University of California, San Francisco
Initiation date: Sep 2009 --> Feb 2012 N=73 --> 21
- | Signifor (pasireotide) / Recordati
Enrollment open: Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases (clinicaltrials.gov) - Feb 8, 2012
P1/2, N=49, Recruiting, Sponsor: Emory University
N=73 --> 21 Not yet recruiting --> Recruiting
- | everolimus / Generic mfg., gemcitabine / Generic mfg.
Enrollment change, Metastases: Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine (clinicaltrials.gov) - Feb 6, 2012
P1/2, N=21, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=61 --> 21
- Avastin (bevacizumab) / Roche
Enrollment closed: Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma (clinicaltrials.gov) - Feb 5, 2012
P2, N=41, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
N=61 --> 21 Recruiting --> Active, not recruiting
- | everolimus / Generic mfg.
New P1/2 trial: CLEVER-ACS: Controlled Level EVERolimus in Acute Coronary Syndromes (clinicaltrials.gov) - Feb 2, 2012
P1/2, N=150, Not yet recruiting, Sponsor: University of Zurich
- everolimus / Generic mfg., fluvastatin / Generic mfg., rosuvastatin / Generic mfg.
New P4 trial: The Rosuvastatin In TrAnsplant Recipients Study (clinicaltrials.gov) - Jan 31, 2012
P4, N=20, Completed, Sponsor: University of Oslo School of Pharmacy
- |||||||||| everolimus / Generic mfg.
New P3 trial, Metastases: RADIANT-4: Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) (clinicaltrials.gov) - Jan 31, 2012
P3, N=302, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- everolimus / Generic mfg.
New P2 trial, Monotherapy, Metastases: Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma (clinicaltrials.gov) - Jan 30, 2012
P2, N=40, Active, not recruiting, Sponsor: Ratchavithi Hospital
- | everolimus / Generic mfg.
New P1 trial, Combination therapy: Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL (clinicaltrials.gov) - Jan 30, 2012
P1, N=42, Recruiting, Sponsor: Dana-Farber Cancer Institute
- ||||| everolimus / Generic mfg., vinorelbine tartrate / Generic mfg.
New P2 trial, Combination therapy, Monotherapy, Metastases: VicTORia: Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer (clinicaltrials.gov) - Jan 25, 2012
P2, N=166, Recruiting, Sponsor: AIO-Studien-gGmbH
- everolimus / Generic mfg.
Trial completion, Monotherapy, Metastases: A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy (clinicaltrials.gov) - Jan 22, 2012
P2, N=40, Completed, Sponsor: Cliniques universitaires Saint-Luc- Universit
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Sutent (sunitinib) / Pfizer
New P4 trial, Metastases: Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib (clinicaltrials.gov) - Jan 19, 2012
P4, N=36, Recruiting, Sponsor: Novartis Pharmaceuticals
- | carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
New P1/2 trial, Metastases: Gastric Cancer RAD001 Study (clinicaltrials.gov) - Jan 18, 2012
P1/2, N=53, Recruiting, Sponsor: Chinese University of Hong Kong
- | Enrollment open: CONCERVIC: Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients (clinicaltrials.gov) - Jan 11, 2012
P4, N=30, Recruiting, Sponsor: Irmandade Santa Casa de Misericórdia de Porto Alegre
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | New P2 trial: PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican (clinicaltrials.gov) - Jan 11, 2012
P2, N=25, Recruiting, Sponsor: Gesellschaft fur Medizinische Innovation
- hydroxychloroquine / Generic mfg., everolimus / Generic mfg., sirolimus / Generic mfg.
New P1/2 trial: Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma (clinicaltrials.gov) - Jan 11, 2012
P1/2, N=25, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- ||||| dactolisib (RTB101) / Adicet Bio
New P1/2 trial, Metastases: Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jan 5, 2012
P1/2, N=54, Recruiting, Sponsor: University of Cincinnati
- everolimus / Generic mfg., sorafenib / Generic mfg.
New P2 trial: study of the combination with sorafenib and everolimus in patients affected by non-resectable high-grade osteosarcoma. Studio sull'associazione di sorafenib ed everolimus in pazienti affetti da osteosarcoma ad alto grado di malignita' non operabile (EUDRACT) - Jan 4, 2012
P2, N=37, Ongoing, Sponsor: ITALIAN SARCOMA GROUP
- oxaliplatin / Generic mfg., everolimus / Generic mfg., capecitabine / Generic mfg.
Enrollment closed, Combination therapy, Metastases: RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX (clinicaltrials.gov) - Dec 30, 2011
P1, N=40, Active, not recruiting, Sponsor: Asan Medical Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| lapatinib / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
New P2 trial, Combination therapy, Metastases: Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer (clinicaltrials.gov) - Dec 22, 2011
P2, N=76, Recruiting, Sponsor: University of Maryland
- ||| Mekinist (trametinib) / Novartis, BeiGene
Trial completion, Combination therapy: A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects (clinicaltrials.gov) - Dec 20, 2011
P1, N=90, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Avastin (bevacizumab) / Roche
Enrollment open, Metastases: Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma (clinicaltrials.gov) - Dec 14, 2011
P2, N=148, Recruiting, Sponsor: North Central Cancer Treatment Group
Active, not recruiting --> Completed Suspended --> Recruiting
- ||||| everolimus / Generic mfg.
New P2 trial, Metastases: RECORD-4: Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Dec 12, 2011
P2, N=135, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- everolimus / Generic mfg.
Enrollment open: Everolimus in Refractory Testicular Germ Cell Cancer (clinicaltrials.gov) - Dec 12, 2011
P2, N=38, Recruiting, Sponsor: National Cancer Institute, Slovakia
Suspended --> Recruiting Not yet recruiting --> Recruiting
- everolimus / Generic mfg.
New P2 trial, Monotherapy: AFINF2: Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients (clinicaltrials.gov) - Dec 11, 2011
P2, N=10, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- ||||| New P1/2 trial: Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer (clinicaltrials.gov) - Dec 11, 2011
P1/2, N=52, Recruiting, Sponsor: Emory University
- everolimus / Generic mfg., docetaxel / Generic mfg.
Trial termination, IO biomarker, Metastases: DORA: Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Dec 8, 2011
P1/2, N=4, Terminated, Sponsor: University College, London
Not yet recruiting --> Recruiting Recruiting --> Terminated; Lack of recruitment
- everolimus / Generic mfg., docetaxel / Generic mfg.
Enrollment change, IO biomarker, Metastases: DORA: Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Dec 8, 2011
P1/2, N=4, Terminated, Sponsor: University College, London
Recruiting --> Terminated; Lack of recruitment N=118 --> 4
- letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Metastases: Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer (clinicaltrials.gov) - Dec 8, 2011
P2, N=42, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=118 --> 4 Recruiting --> Active, not recruiting
- ||||||| Trial completion: Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation (clinicaltrials.gov) - Dec 6, 2011
P3, N=190, Completed, Sponsor: Hannover Medical School
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- everolimus / Generic mfg.
New P2 trial, Metastases: Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 6, 2011
P2, N=30, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment open, Metastases: ROPETAR: Rotating Pazopanib and Everolimus to Avoid Resistance (clinicaltrials.gov) - Dec 4, 2011
P2, N=100, Recruiting, Sponsor: Netherlands Working Group on Immunotherapy of Oncology
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | everolimus / Generic mfg.
New P2 trial: Efficacy of RAD001/everolimus in Autism and NeuroPsychological deficits in children with tuberous sclerosis complex (RAPIT-trial) Onderzoek naar behandeling van leer- en gedragsproblemen bij kinderen met Tubereuze Sclerose Complex met RAD001 (EUDRACT) - Nov 30, 2011
P2, N=60, Ongoing, Sponsor: Erasmus MC - Department of Neurology
- | carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Enrollment open, Metastases: RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation (clinicaltrials.gov) - Nov 29, 2011
P4, N=47, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- everolimus / Generic mfg.
New P2 trial, Metastases: RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression (clinicaltrials.gov) - Nov 28, 2011
P2, N=45, Active, not recruiting, Sponsor: Asan Medical Center
- | dactolisib (RTB101) / Adicet Bio
New P1 trial, Combination therapy, Metastases: Dose Finding Study of RAD001 (Everolimus, Afinitor (clinicaltrials.gov) - Nov 28, 2011
P1, N=46, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- everolimus / Generic mfg., erlotinib / Generic mfg.
Trial termination, Combination therapy: A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors (clinicaltrials.gov) - Nov 20, 2011
P1, N=85, Terminated, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Recruiting --> Terminated; Primary objective has been met; safety and pharmacokinetics have been characterized.
- | everolimus / Generic mfg.
Enrollment change: Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) (clinicaltrials.gov) - Nov 17, 2011
P4, N=20, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Terminated; Primary objective has been met; safety and pharmacokinetics have been characterized. N=40 --> 20
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion, Combination therapy: Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Nov 15, 2011
P2, N=25, Completed, Sponsor: Massachusetts General Hospital
N=40 --> 20 Active, not recruiting --> Completed
- |||| Simulect (basiliximab) / Novartis, sotrastaurin (AEB071) / Novartis
Trial completion, Combination therapy: Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients (clinicaltrials.gov) - Nov 14, 2011
P2, N=311, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed